Derma Sciences Inc

Type: Company
Name: Derma Sciences Inc
First reported 22 hours ago - Updated 22 hours ago - 1 reports

Derma Sciences receives approval for inclusion of AMNIOEXCEL in FSS

Derma Sciences, Inc., a tissue regeneration company focused on wound care, has received approval from the Veterans Administration, or VA, for AMNIOEXCEL, the company's novel human amniotic membrane allograft, for inclusion in its Federal Supply Schedule, ... [Published Individual.com - 22 hours ago]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Derma Sciences Reports VA OKs Amnioexcel for Federal Supply Schedule V797P-2000D [Professional Services Close - Up]

Derma Sciences reported that Amnioexcel, its novel human amniotic membrane allograft, has been approved by the Veterans Administration for inclusion in its Federal Supply Schedule V797P-2000D."Inclusion in the Federal Supply Schedule is an important milestone ... [Published Pharmacy Choice - Jul 29 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

COMVITA : Derma Sciences CEO Discusses Continued Growth of MEDIHONEY at Comvita Annual Meeting of Shareholders

Comvita supplies medical grade Manuka honey to Derma Sciences for use in the MEDIHONEY product line. In September 2013 Derma Sciences made a $7.0 million equity investment in Comvita , representing a 7.2% ownership stake, in order to solidify its honey ... [Published 4 Traders - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Derma Sciences CEO Discusses Continued Growth of MEDIHONEY® at Comvita Annual Meeting of Shareholders

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announces that Edward J. Quilty, its chief executive officer, delivered a presentation highlighting MEDIHONEY® and its ... [Published Business Wire Health News - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Derma Sciences: VA Approves Amnioexcel for Federal Supply Schedule V797P-2000D

Derma Sciences reported that Amnioexcel, its novel human amniotic membrane allograft, has been approved by the Veterans Administration for inclusion in its Federal Supply Schedule V797P-2000D. "Inclusion in the Federal Supply Schedule is an important ... [Published Individual.com - Jul 25 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 2 reports

Derma Sciences announces Veterans Administration adds AMNIOEXCEL® to its Federal Supply Schedule

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announces that AMNIOEXCEL®, its novel human amniotic membrane allograft, has been approved by the Veterans Administration ... [Published Business Wire Technology News - Jul 22 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 2 reports

Market Report, "Derma Sciences, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report", Published

Boston, MA -- (SBWIRE) -- 07/18/2014 -- The Derma Sciences, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, ... [Published CW Atlanta - Jul 18 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 2 reports

Use This Winning Strategy Before You Chase A Falling Stock

If you're like most investors, then you probably repeatedly made the same mistake as you learned the rules of the game.You likely spotted a great bargain stock, bought shares and waited for something to happen. Shares likely stayed stuck at bargain levels, ... [Published StreetAuthority - Jun 27 2014]
First reported Jun 21 2014 - Updated Jun 21 2014 - 1 reports

Derma Sciences CEO on exciting new wound drug

Ed Quilty of Derma Sciences talks about the need for perseverance in the process of drug development, and in building a career ... [Published Latest Econwatch Headlines - CBS News - Jun 21 2014]
First reported Jun 13 2014 - Updated Jun 13 2014 - 3 reports

Derma Sciences, Inc. to Webcast June 17th Analyst Day

PRINCETON, N.J.--(EON: Enhanced Online News)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces it will be webcasting its Analyst Day event to be held June 17 in New York City. The program’s ... [Published EON Science - Jun 13 2014]
First reported May 08 2014 - Updated May 09 2014 - 3 reports

Derma Sciences Reports First Quarter Financial Results

PRINCETON, N.J.--(EON: Enhanced Online News)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three months ended March 31, 2014. Highlights ... [Published EON Business - May 08 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 3 reports

Derma Sciences Reports Fourth Quarter Financial Results, Provides Commercial Update Including Sales Force Expansion and Progress in Launching New Placental-Derived Tissue Products

PRINCETON, N.J.--(EON: Enhanced Online News)--Derma Sciences, Inc. (the “Company”) (Nasdaq:DSCI), a tissue regeneration and burn care company focused on advanced wound care, today reported financial and operating results for the three months and year ... [Published EON Science - Mar 14 2014]

Quotes

"Inclusion in the Federal Supply Schedule is an important milestone for our newly acquired AMNIO product line as we continue to position Derma Sciences as a leading wound care company specializing in tissue regeneration" said Edward J Quilty, CEO of Derma Sciences
Barry Wolfenson, group president of advanced wound care and drug development at Derma Sciences, said, "With this approval, we can now implement the next part of our business plan by achieving more widespread utilization of Amnioexcel in this $500 million market. This will help us to develop an even broader base of key opinion leaders, which will be critical as we work diligently to secure coverage from the Medicare Administrative Contractors. We look forward to announcing our progress in this area in the coming months."
Brett Hewlett , chief executive officer of Comvita , said, " Derma Sciences has been a wonderful partner and we continue to be very pleased with the sustained growth of MEDIHONEY they have delivered over the past few years. With a three-year compound annual growthgrowth rate of 36% through June 2014 and expansion to new indications such as burns, radiation oncology and acute care, we are confident that Derma Sciences will continue to be the excellent partner it has proven itself to be thus far."
...with diabetic macular edema,” said Scott M Whitcup, M D , Allergan’s Executive Vice President, Research and Development, Chief Scientific Officer. "DME is a complicated disease to treat, and the additional license for OZURDEX® in the EU would offer another important treatment option to help preserve vision for patients.”"

More Content

All (45) | News (15) | Reports (0) | Blogs (30) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Derma Sciences receives approval for inclusion ... [Published Individual.com - 22 hours ago]
Derma Sciences Reports VA OKs Amnioexcel for Fe... [Published Pharmacy Choice - Jul 29 2014]
COMVITA : Derma Sciences CEO Discusses Continue... [Published 4 Traders - Jul 28 2014]
Bioheart Announces World's First Combination St... [Published BioMedReports - Jul 26 2014]
Derma Sciences CEO Discusses Continued Growth o... [Published Business Wire Health News - Jul 25 2014]
Derma Sciences: VA Approves Amnioexcel for Fede... [Published Individual.com - Jul 25 2014]
Advanced Wound Care and Closure Market to Reach... [Published Yahoo! Finance - Jul 22 2014]
Derma Sciences announces Veterans Administratio... [Published Business Wire Technology News - Jul 22 2014]
Derma Sciences announces Veterans Administratio... [Published Business Wire Health News - Jul 22 2014]
Market Report, "Derma Sciences, Inc. - Mergers ... [Published CW Atlanta - Jul 18 2014]
Market Report, "Derma Sciences, Inc. - Mergers ... [Published Myrtle Beach Sun News - Jul 18 2014]
Comvita ends strong year [Published Sun Live - Jun 28 2014]
Use This Winning Strategy Before You Chase A Fa... [Published StreetAuthority - Jun 27 2014]
Use This Winning Strategy Before You Chase A... [Published Nasdaq - Jun 27 2014]
Advanced Wound Care Markets Worldwide [Published MarketResearch.com - Jun 24 2014]
Derma Sciences CEO on exciting new wound drug [Published CBS News - Jun 23 2014]
Derma Sciences CEO on exciting new wound drug [Published Latest Econwatch Headlines - CBS News - Jun 21 2014]
Derma Sciences, Inc. to Webcast June 17th Analy... [Published EON Science - Jun 13 2014]
Derma Sciences, Inc. to Webcast June 17th Analy... [Published Business Wire Science: Science News - Jun 13 2014]
Derma Sciences, Inc. to Webcast June 17th Analy... [Published Business Wire Health News - Jun 13 2014]
Research and Markets: Global Diabetic Neuropath... [Published Yahoo! Finance - May 16 2014]
Derma Sciences Reports First Quarter Financial ... [Published EON Business - May 08 2014]
Derma Sciences Reports First Quarter Financial ... [Published Business Wire Professional Services News - May 08 2014]
Derma Sciences Reports First Quarter Financial ... [Published Business Wire Health News - May 08 2014]
Derma Sciences to Present at Sidoti Semiannual ... [Published Business Wire Health News - May 06 2014]
Derma Sciences to Hold First Quarter Financial ... [Published Business Wire Health News - Apr 30 2014]
3 Stocks Under $10 Making Big Moves [Published The Street Latest - Apr 30 2014]
Derma Sciences Products to Be Featured in 10 Po... [Published Business Wire Health News - Apr 23 2014]
Derma Sciences Reports Fourth Quarter Financial... [Published EON Science - Mar 14 2014]
Derma Sciences Reports Fourth Quarter Financial... [Published Business Wire Science: Science News - Mar 14 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Derma Sciences CEO Discusses Continued Growth o... [Published Business Wire Health News - Jul 25 2014]
PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announces that Edward J. Quilty, its chief executive officer, delivered a presentation highlighting MEDIHONEY® and its ...
Derma Sciences announces Veterans Administratio... [Published Business Wire Technology News - Jul 22 2014]
PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announces that AMNIOEXCEL®, its novel human amniotic membrane allograft, has been approved by the Veterans Administration ...
Derma Sciences announces Veterans Administratio... [Published Business Wire Health News - Jul 22 2014]
PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announces that AMNIOEXCEL®, its novel human amniotic membrane allograft, has been approved by the Veterans Administration ...
Derma Sciences CEO on exciting new wound drug [Published Latest Econwatch Headlines - CBS News - Jun 21 2014]
Ed Quilty of Derma Sciences talks about the need for perseverance in the process of drug development, and in building a career ...
Derma Sciences, Inc. to Webcast June 17th Analy... [Published EON Science - Jun 13 2014]
PRINCETON, N.J.--(EON: Enhanced Online News)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces it will be webcasting its Analyst Day event to be held June 17 in New York City. The program’s ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.